Unique mechanisms of connective tissue growth factor regulation in airway smooth muscle in asthma: Relationship with airway remodelling

Junfei Wang1,2 | Alen Faiz3,4,5 | Qi Ge2,6 | Cornelis J. Vermeulen3,4 | Joanne Van der Velden7 | Kenneth J. Snibson7 | Rob van de Velde2 | Sonia Sawant2 | Dikaia Xenaki2 | Brian Oliver2,8 | Wim Timens4,5 | Nick ten Hacken3,4 | Maarten van den Berge3,4 | Alan James9,10 | John G. Elliot9 | Liang Dong1 | Janette K. Burgess2,4,5,6 | Anthony W. Ashton11

1Department of Pulmonary Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China
2Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia
3University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, The Netherlands
4University of Groningen, University Medical Center Groningen, GRIAC (Groningen Research Institute for Asthma and COPD), Groningen, The Netherlands
5University of Groningen, University Medical Center Groningen, Department of Pathology & Medical Biology, Groningen, The Netherlands
6Discipline of Pharmacology, The University of Sydney, Sydney, NSW, Australia
7Faculty of Veterinary and Agricultural Science, Melbourne Veterinary School, University of Melbourne, Parkville, Vic., Australia
8School of Life Sciences, University of Technology, Sydney, NSW, Australia
9Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia
10School of Medicine and Pharmacology, The University of Western Australia, Perth, WA, Australia
11Division of Perinatal Research, Kolling Institute of Medical Research, Sydney, NSW, Australia

Abstract
Neovascularization, increased basal membrane thickness and increased airway smooth muscle (ASM) bulk are hallmarks of airway remodelling in asthma. In this study, we examined connective tissue growth factor (CTGF) dysregulation in human lung tissue and animal models of allergic airway disease. Immunohistochemistry revealed that ASM cells from patients with severe asthma (A) exhibited high expression of CTGF compared to mild and non-asthmatic (NA) tissues. This finding was replicated in a sheep model of allergic airways disease. In vitro, transforming growth factor (TGF)-β increased CTGF expression both in NA- and A-ASM cells but the expression was higher in A-ASM at both the mRNA and protein level as assessed by PCR and Western blot. Transfection of CTGF promoter-luciferase reporter constructs into NA- and A-ASM cells indicated that no region of the CTGF promoter (−1500 to +200 bp) displayed enhanced activity in the presence of TGF-β.
INTRODUCTION

Asthma is a common, chronic respiratory disease affecting more than 300 million people worldwide. The main characteristics of asthma are airway inflammation, airway hyper-responsiveness and airway remodelling. The structural changes in the airways, termed airway remodelling, include increased airway smooth muscle (ASM) bulk, increased basal membrane thickness and vascular expansion. The extent of airway way remodelling correlates with several clinical features of asthma and agents that normalize the remodelling response potentially improve asthma symptoms. Once considered a manifestation of chronic inflammation, recent studies have identified remodelling is a separate but parallel component of the asthmatic process.

In asthma, the observed increase in ASM cell bulk and contractility directly mediates airway narrowing and is central to the process of airway remodelling. Increased ASM number correlates with increased reticular basement membrane (BM) thickness and eosinophilia, but not neutrophilia. Further, the secretory profiles of ASM from asthmatic patients differ significantly from those of non-asthmatic patients suggesting that paracrine signalling from the ASM in may have as much to do with airway remodelling as their contractile state (reviewed in Ref. [14]). Ultimately, the increased deposition of extracellular matrix (ECM) proteins by ASM cells in asthma is key to the airway narrowing that takes place. Often this is a response to an imbalance in the cytokines/growth factors present in their local milieu.

In lung tissue, ASM cells are a potent source of connective tissue growth factor (CTGF), a member of the cysteine-rich 61, CTGF, nephroblastoma (CCN) family of proteins. Our previous studies have shown greater CTGF expression in primary asthmatic (A)-ASM cells than non-asthmatic (NA)-ASM cells after TGF-β treatment. CTGF controls ECM deposition and ultimately airway biomechanics through changes to collagen deposition which increase ECM density and airway stiffness. Indeed, the increased stiffness of the matrix in which asthmatic ASM cells are embedded promotes a more proliferative and pro-inflammatory ASM phenotype.

The mechanisms underlying the differential regulation of CTGF expression in A-ASM are not currently known. Studies in other systems have reported that CTGF induction by TGF-β is regulated through interactions of transcription factors with promoter elements directly upstream of the promoter start site. In this study, we investigated the mechanisms that enhance TGF-β induction of CTGF release from A-ASM cells and the potential links to airway remodelling in asthma.

MATERIALS AND METHODS

Primary ASM cell isolation and culture

Approval for experiments with human lung tissue was provided by the Ethics Review Committee of the South West Sydney Area Health Service, St Vincent’s Hospital Sydney, Strathfield Private Hospital, Royal Prince Alfred Hospital and the University of Sydney Human Research Ethics Committee. Primary human ASM cells were obtained through dissection of donated lung tissue following transplantation and from endobronchial biopsies from volunteers who provided written informed consent, as described previously. The patients’ details are described in Table 1.

Cells were grown in 10% (v/v) foetal bovine serum (FBS) (RJR Biosciences, Brooklyn, VIC, Australia)/high glucose Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA) containing 100 units/mL of penicillin, 100 µg/mL of streptomycin, 0.25 µg/mL of amphotericin B (Thermo Fisher, Waltham, MA, USA) and 25 mmol/L HEPES (Sigma-Aldrich). Use of primary ASM cells was restricted to passage numbers 2 and 8.

Detection of CTGF by immunohistochemistry

Sections from archived paraffin-embedded lung tissue were obtained from non-, mild and severely asthmatic patients as well as a sheep model of allergic airways disease that had been previously described. Slides were de-paraffinized in xylene and rehydrated through graded ethanol solutions. Peroxidase-blocking solution (DAKO, Agilent Pathology, Foster City, CA, USA) was used to block endogenous peroxidases at 37°C for 15 minutes. Slides were washed and incubated with serum-free protein block (DAKO) at
37°C for 30 minutes followed by incubation with rabbit anti-CTGF primary antibody (2.5 μg/mL for human, 5 μg/mL for sheep lung tissue, ab6922; Abcam, Cambridge, UK) or rabbit IgG (same concentration as CTGF antibody, X0903, DAKO) overnight at 4°C. Primary antibodies were diluted in REAL antibody diluent (DAKO) to minimize non-specific binding. After washing, slides were incubated with EnVision+ system HRP labelled polymer anti-rabbit secondary antibody (K4003, DAKO) for 45 minutes at 37°C. Liquid diaminobenzidine (DAB) substrate chromogen system (DAKO) was added and + oxidation-conjugated secondary antibody (1:2000 for CTGF [P0160], DAKO) at 4°C overnight. Membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibody (1:100 Protease Inhibitor Cocktail Set III [Merck Millipore, Billerica, MA, USA]) and stored at −20°C until analysis.

2.3 | ASM cell stimulation

For all experiments, unless otherwise indicated, ASM cells were seeded into 6-well plates at a concentration of 1 × 10⁴ cells/cm² in 5% (v/v) FBS/DMEM and grown for 3 days before being made quiescent in 0.1% (v/v) bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO, USA)/DMEM for 24 hours. Cells were treated with recombinant human TGF-β1 protein (1 ng/mL, R&D systems, Minneapolis, MN, USA) for the indicated durations. Cells were washed twice with ice-cold phosphate-buffered saline (PBS, Sigma-Aldrich) and lyzed in lysis buffer prior to total RNA being extracted using the ISOLATE RNA mini kit (Bioline, London, UK) according to the manufacturer’s instructions, quantified with a NanoDrop 2000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and stored in −20°C for further use. Alternately, cells were scraped into protein lysis buffer (20 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L Na₂EDTA, 1 mmol/L EGTA, 1 mmol/L NaF, 20 mmol/L Na₃P₂O₇, 2 mmol/L Na₃VO₄, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1 mmol/L phenylmethylsulphonyl fluoride and 1:100 Protease Inhibitor Cocktail Set III [Merck Millipore, Billerica, MA, USA]) and stored at −20°C until analysis.

2.4 | Real-time reverse transcription polymerase chain reaction

To investigate CTGF mRNA expression, real-time PCR was conducted on NA- and A-ASM cells with primers and probe specific to CTGF (Hs01026927_g1, Life Technologies, Carlsbad, CA, USA) and BioSense SensiFast™ Probe Hi-ROX Mastermix (Bioline) using a StepOne Plus detection system (Thermo Fisher). Relative gene expression between treatments was calculated using the 2⁻ΔΔCt method after normalization against the 18s rRNA probe (4319413E-1011052, Life Technologies).

2.5 | Western blot

Total cellular protein was extracted and separated on a 10% (w/v) SDS-PAGE gel, and transferred to polyvinylidene difluoride membrane (Merck Millipore). Membranes were blocked in 5% (w/v) skim milk in Tris-buffered saline (TBS, 20 mmol/L Tris base, 150 mmol/L NaCl, PH7.4) containing 0.05% (v/v) Tween 20 for 30 minutes at room temperature and incubated with goat polyclonal anti-CTGF antibody (1:1000, sc-14939, Santa-Cruz Biotechnology, Dallas, TX, USA) or anti-GAPDH (1:10 000, MAB-374; Millipore) at 4°C overnight. Membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibody (1:2000 for CTGF [P0160], 1:50 000 for GAPDH [P0161], DAKO). Images were captured using a Kodak Image station 4000 mm, and band intensity was quantified with Carestream MI SE software.

2.6 | CTGF promoter constructs

A Gluc-on reporter plasmid containing the full-length CTGF promoter (−1500 to −200 bp) driving expression of a secreted Gaussia

---

**TABLE 1** Details of asthmatic and non-asthmatic donors

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Sample type</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>67</td>
<td>Male</td>
<td>Healthy</td>
<td>Transplant</td>
</tr>
<tr>
<td>2</td>
<td>47</td>
<td>Male</td>
<td>Healthy</td>
<td>Transplant</td>
</tr>
<tr>
<td>3</td>
<td>22</td>
<td>Female</td>
<td>Healthy</td>
<td>Biopsy</td>
</tr>
<tr>
<td>4</td>
<td>64</td>
<td>Male</td>
<td>ILD</td>
<td>Transplant</td>
</tr>
<tr>
<td>5</td>
<td>76</td>
<td>Male</td>
<td>Pulmonary cryptococcosis</td>
<td>Resection</td>
</tr>
<tr>
<td>6</td>
<td>61</td>
<td>Female</td>
<td>Pulmonary hypertension</td>
<td>Transplant</td>
</tr>
<tr>
<td>7</td>
<td>41</td>
<td>Female</td>
<td>Adenocarcinoma</td>
<td>Resection</td>
</tr>
<tr>
<td>8</td>
<td>29</td>
<td>Male</td>
<td>Healthy</td>
<td>Biopsy</td>
</tr>
<tr>
<td>9</td>
<td>16</td>
<td>Male</td>
<td>Healthy</td>
<td>Transplant</td>
</tr>
<tr>
<td>10</td>
<td>65</td>
<td>Male</td>
<td>Cancer</td>
<td>Resection</td>
</tr>
<tr>
<td>11</td>
<td>27</td>
<td>Female</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>12</td>
<td>54</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>13</td>
<td>23</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>14</td>
<td>58</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>15</td>
<td>21</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>16</td>
<td>38</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>17</td>
<td>61</td>
<td>Female</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>18</td>
<td>85</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>19</td>
<td>51</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>20</td>
<td>63</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>21</td>
<td>59</td>
<td>Female</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>22</td>
<td>64</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>23</td>
<td>NA</td>
<td>NA</td>
<td>Healthy</td>
<td>Transplant</td>
</tr>
<tr>
<td>24</td>
<td>52</td>
<td>Male</td>
<td>Cancer</td>
<td>Resection</td>
</tr>
<tr>
<td>25</td>
<td>22</td>
<td>Male</td>
<td>Healthy</td>
<td>Biopsy</td>
</tr>
<tr>
<td>26</td>
<td>60</td>
<td>Female</td>
<td>Cancer</td>
<td>Resection</td>
</tr>
<tr>
<td>27</td>
<td>27</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>28</td>
<td>33</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
<tr>
<td>29</td>
<td>50</td>
<td>Male</td>
<td>Asthmatic</td>
<td>Biopsy</td>
</tr>
</tbody>
</table>

ILD, interstitial lung disease; NA, not available.
luciferase was purchased from GeneCopoeia (Cat. HPRM25713-PG04, Rockville, MD, USA). A series of 5’ deleted constructs were generated by PCR using the primers shown in Table 2. The full-length CTGF promoter was excised using the restriction enzymes Hind III and Bgl II (New England Labs, Ipswich, MA, USA) and the generated PCR products ligated into the vector using T4 DNA ligase (Promega, Madison, WI, USA). All constructs were sequence verified at the Australian Genome Research Facility (Melbourne, Vic., Australia) prior to expansion and transfection.

2.7 | Transfection and luciferase assay

Airway smooth muscle cells and NIH-3T3 mouse embryonic fibroblasts were seeded in 12-well plates at densities of 1 × 10^5 cells/cm² and 8 × 10^4 cells per well, respectively, for 24 hours in 10% (v/v) FBS/DMEM. The full-length CTGF promoter, or the 5’ deleted constructs, were transfected into the indicated cells using Lipofectamine 3000 (L-3000075; Invitrogen, Carlsbad, CA, USA) transfection reagent according to the manufacturer’s instructions using either 1 or 1.6 μg of plasmid DNA for ASM and NIH-3T3 cells, respectively.

Cells were stimulated with TGF-β1 (1 ng/mL for ASM and 10 ng/mL for NIH-3T3) 24 hours after transfection, for a further 24 hours. The supernatant was collected for luciferase detection by Secrete-Pair™ Dual Luminescence Assay Kit (GeneCopoeia) and total RNA isolated from the cell monolayers using the ISOLATE RNA mini kit (Bioline) for CTGF mRNA detection.

2.8 | Analysis of distant transcription factor binding sites with potential to regulate CTGF promoter

To investigate other potential transcription factor binding sites in close proximity to the CTGF promoter, H3K27Ac binding (a marker of transcription factor binding) was investigated. This analysis was conducted using chromatin immunoprecipitation sequence (ChIP-Seq) data on human umbilical vein endothelial cells (HUVECs), mouse embryonic (NIH-3T3) and normal human lung (NHLF) fibroblasts generated as part of the Encyclopedia of DNA Elements (ENCODEx) Project (GSE29611).

2.9 | Assessment of mRNA stability in ASM cells

To measure CTGF mRNA stability, ASM cells rendered quiescent by incubation in 0.1% (w/v) BSA/DMEM for 24 hours were treated with TGF-β1 (1 ng/mL) for 8 hours. After washing with PBS, actinomycin D (10 μg/mL, Sigma-Aldrich) was added to the media for a further 0-16 hours as indicated. Total RNA was isolated, and CTGF mRNA was quantified by PCR as described above.

2.10 | CTGF gene expression relationship with clinical factors

We obtained high-quality RNAseq data from 184 biopsies. Biopsies were derived from 77 healthy individuals and 107 current or}

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Primer sequence (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>−100 forward</td>
<td>ATC GAG ATC TAA CAA CAT AGA TTC CAA ATG A</td>
</tr>
<tr>
<td>−400 forward</td>
<td>ATC GAG ATC TGT AAT GGA ATC AGA CTT CTT A</td>
</tr>
<tr>
<td>−700 forward</td>
<td>ATC GAG ATC TAA AAC TAA GCA AGA GTT TTG G</td>
</tr>
<tr>
<td>−1000 forward</td>
<td>ATC GAG ATC TCT TCA GCT ACC TAC TTC CTA A</td>
</tr>
<tr>
<td>−1300 forward</td>
<td>ATC GAG ATC TAT GCG AGG AAT GTC CCT GTT T</td>
</tr>
</tbody>
</table>

Reverse primer ATC CGA GCT CGG TAC CAA CAT T

CTGF, connective tissue growth factor.

FIGURE 1  Connective tissue growth factor (CTGF) expression is increased in house dust mite (HDM)-induced allergic airway disease in sheep lungs. CTGF expression in a model of allergic airway disease was assessed by immunohistochemistry in HDM- and saline-exposed (sham control) lung segments from the same sheep^20 (n = 5). Isotype-matched negative control antibody on serial sections shown for comparison. Representative images shown for each group.
Asthmatic airway smooth muscle (ASM) cells have different kinetics of connective tissue growth factor (CTGF) induction. ASM cells from A- and NA-donors were stimulated with transforming growth factor (TGF)-β (1 ng/mL) for up to 72 h and CTGF transcript (A; NA-ASM [n = 7] and A-ASM [n = 5]) and protein (B; NA-ASM [n = 4] and A-ASM [n = 7]) levels examined by Q-PCR and Western blot, respectively. Representative images of Western blots are shown. Changes in CTGF expression by Western blot were quantified using image J software (C). *P < .05, **P < .01 and ***P < .001 denotes significance between bovine serum albumin and TGF-β. #P < .05, ##P < .01 and ####P < .0001, # indicates significant difference between NA- and A-ASM cells.
a new regulatory element emerge in the full-length or any of the truncated mutants. This was in direct contrast to CTGF mRNA expression which increased in both NA (Figure 3C) and A (Figure 3E)-ASM cells after TGF-β treatment in the presence of all transfections.

3.3 | Tissue specific genetic elements indicate CTGF regulation in lung tissue is unique

To assess whether our promoter construct was indeed inducible by TGF-β and to determine whether CTGF regulation in ASM was

---

**FIGURE 3** Basal regulation of the connective tissue growth factor (CTGF) promoter is the same in NA- and A-ASM cells. A. Schematic of the 5’ deleted CTGF promoter constructs used to examine regulation in NA- and A-ASM cells. Different lengths of the human CTGF promoter (−1500 to +200) were placed upstream of a Luciferase reporter construct (l). Secretion of alkaline phosphatase (SEAP) expression was driven by CMV promoter in the same construct and was used as a control for transfection efficiency. Luciferase activity in conditioned media was detected after stimulation of transfected ASM cells with TGF-β (1 ng/mL; NA; B, n = 5 and A-ASM; D, n = 5). CTGF mRNA in NA (C) and A-ASM (E) was measured by Q-PCR in the same cells used for luciferase assays to determine the effectiveness of induction for the endogenous gene. “&” Denotes significance between promoter-less (0) and luciferase reporter (&&P < .05, &&&P < .01, &&&&P < .001). *Indicates significant difference of CTGF mRNA expression between TGF-β and BSA, *P < .05, **P < .01, ****P < .0001. ASM, asthmatic airway smooth muscle; BSA, bovine serum albumin.
different to other tissues, we transfected NIH-3T3 cells and examined luciferase activity. Previous reports have shown that CTGF promoter-luciferase reporter constructs increase activity 2- to 4-fold when NIH-3T3 cells are stimulated with TGF-β.25,27,33,34 Indeed, treatment of transfected NIH-3T3 fibroblasts with TGF-β induced a 2-fold increase in luciferase expression compared to unstimulated cells (Figure S1) indicating our CTGF promoter construct (−400 to −200) was indeed inducible but just not in human ASM cells.

Having found that the CTGF promoter regulation in human ASM cells differed from that reported in other cell lines,25,27,33,34 we investigated regions of transcription factor binding activity surrounding the CTGF transcriptional start site to look for additional regulatory elements. This analysis was conducted by investigating H3K27Ac binding (a marker of transcription factor binding). For this analysis, we used human lung fibroblasts as previously no differences in gene expression were detected between lung fibroblasts and ASM cells, indicating highly similar gene expression regulation.35 There was a strong region of activity immediately upstream of the CTGF transcriptional start site in HUVECs (−1300 to −200 bp), which was less active in human lung fibroblasts (Figure 4A). This region spanned the −1500 bp promoter construct we had analysed (Figure 4B), and contained several validated SMAD and TGF-β response elements previously reported to drive CTGF expression in other species (Figure 4C, Table 3).25,27,36 However, an alternate genomic region 5′ to the (−1300 to −200 bp) site (−4200 to −2400 bp) showed robust H3K27Ac binding in lung cells but relatively low activity in HUVECs (Figure 4A). These findings suggest that this region may be responsible for the alternative regulation of CTGF expression in human lung cells.

3.4 | CTGF mRNA stability is enhanced in asthmatic ASM cells

Ibrul Chowdhury et al previously reported that FBS-induced CTGF mRNA expression was regulated by both new transcription and mRNA stabilization in primary bladder smooth muscle cells.37 To further characterize the regulation of CTGF in A- and NA-ASM cells, we compared the kinetics of CTGF RNA turnover induced by TGF-β. In NA-ASM cells, CTGF transcripts were rapidly degraded, with a half-life of 3 hours (Figure 5). In contrast, the half-life of CTGF mRNA in A-ASM cells was prolonged (7 hours) suggesting that the mRNA stability was enhanced in the A-ASM cells. Linear regression showed that the degradation rate after 6 hours between A- (k = −2.99) and NA- (k = −2.42) ASM cells was similar. However, in NA-ASM cells, the degradation of CTGF mRNA in the first 6 hours was 20.3% higher than in the A-ASM cells (k = −15.82 vs k = −12.6, respectively) suggesting enhanced stability and slower degradation are the source of the longer mRNA half-life in A-ASM cells. These data suggested that TGF-β-induced CTGF mRNA in

**FIGURE 4** Differential usage of promoter elements endows cell-type specific regulation of connective tissue growth factor (CTGF) in asthmatic airway smooth muscle. A, H3K27ac profiling from human lung fibroblasts and HUVECs surrounding the CTGF gene by ChIP-Seq. B, Plasmid CTGF promotor construct used in this project. C, Validated SMAD and transforming growth factor (TGF)-β transcription factor binding sites across difference species. HUVECs, human umbilical vein endothelial cells; SMAD, similar to mothers against decapentaplegic. Analysis was performed using the ENCODE database.
A-ASM cells was more stable than NA-ASM cells providing a possible explanation for the differential expression of TGF-β-induced CTGF between A- and NA-ASM cells.

### TABLE 3  TGF-β transcription factor binding sites across difference species

<table>
<thead>
<tr>
<th>Cells type</th>
<th>Transcription factor</th>
<th>Binding site in CTGF promoter</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH-3T3 fibroblast</td>
<td>Smad3,34,58</td>
<td>−173 to −166</td>
</tr>
<tr>
<td></td>
<td>TGF-β responsive</td>
<td>−246 to −166</td>
</tr>
<tr>
<td></td>
<td>element24,58</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ets159</td>
<td>−126 to −77</td>
</tr>
<tr>
<td>Nucleus pulposus cells</td>
<td>Smad26</td>
<td>−173 to −166</td>
</tr>
<tr>
<td>C3H10T1/2</td>
<td>Smad25</td>
<td>−173 to −166</td>
</tr>
<tr>
<td>Scleroderma fibroblast</td>
<td>Smad58</td>
<td>−173 to −166</td>
</tr>
<tr>
<td></td>
<td>TGF-β responsive</td>
<td>−246 to −166</td>
</tr>
<tr>
<td></td>
<td>element58</td>
<td></td>
</tr>
<tr>
<td>Osteoblast</td>
<td>Smad60</td>
<td>−173 to −166</td>
</tr>
<tr>
<td></td>
<td>Ets142</td>
<td>−126 to −77</td>
</tr>
</tbody>
</table>

CTGF, connective tissue growth factor; TGF, transforming growth factor.

### FIGURE 5  Connective tissue growth factor (CTGF) mRNA stability is enhanced in A-ASM cells. NA- (n = 4) and A-ASM cells (n = 5) were treated with TGF-β (1 ng/mL) with actinomycin D (10 μg/mL) added after 8 h for up to 16 h. CTGF mRNA expression was measured by Q-PCR to assess the rate of turnover. *Means significant difference in CTGF mRNA expression to time 0, **P < .05, ***P < .001, ****P < .0001. #P < .05 indicates a significant difference between NA- and A-ASM. ASM, asthmatic airway smooth muscle; TGF, transforming growth factor.

### FIGURE 6  Connective tissue growth factor (CTGF) expression and correlations with clinical indices in asthmatic patients. A, CTGF expression was assessed by immunohistochemistry in human lung tissue (n = 5 for healthy control, mild asthma and severe asthma). Representative images shown for each group. B-E, CTGF mRNA expression fragments per kilobase million (FPKM) was detected in bronchial biopsies from healthy controls and mild asthmatic patients (B). A linear model comparing the association between CTGF expression in asthmatic bronchial biopsies and BM thickness (μmol/L) (C), FEV1% predicted (D), % of sputum eosinophils (E) and PC20 mg/mL (F) was conducted correcting for age, gender and smoking status. *, correlation co-efficient; P, significance value of the correlation. BM basement membrane, FEV1% predicted forced expiratory volume in 1 s percentage predicted, PC20 the concentration of methacholine needed to produce a 20% fall in FEV1 from baseline. See Ref. [32] (Table 1) for lung function on this cohort.

### 3.5  CTGF gene expression is unchanged in mild asthmatic patients but relates to BM thickness

Immunohistochemical staining showed CTGF protein expression was concentrated in the ASM area in human lung tissue, with enhanced detection visible in asthmatic tissues, particularly from severe asthma patients (Figure 6A). No difference in CTGF mRNA expression (Figure 6B) was detected between bronchial biopsies derived from mild to moderately severe asthma patients (n = 69) and healthy controls (n = 77). In addition, within asthmatic patients, we found a significant relationship between CTGF expression and BM thickness (β ± SE 0.472 ± 0.174, P = .008, Figure 6C) suggesting ASM-derived CTGF expression may influence airway narrowing and remodelling in asthma. In contrast, higher CTGF expression in asthmatic patients was not associated with lower FEV1% predicted (Figure 6D), more severe bronchial hyper-responsiveness (Figure 6F) or higher % eosinophil levels in sputum (Figure 6E).

### 4  DISCUSSION

This is the first study that has focused on the molecular regulation of CTGF mRNA in primary ASM cells. Tissue localization in asthmatic airways indicated that the ASM cells were the primary location of CTGF expression. We have shown that, unlike other cell types, regulation of CTGF mRNA expression in primary ASM cells may not be located in the first 1500 bases in the CTGF promoter, but rather lie some distance upstream. In addition, post-transcriptional regulation of mRNA stability plays a role in the differential TGF-β-induced CTGF mRNA expression in A- and NA-ASM cells. CTGF expression in asthmatic patients correlated with the degree of BM thickening, suggesting CTGF may contribute to the mechanisms driving airway remodelling.

In our study, we observed greater CTGF expression in airway tissues taken from lung segments of sheep chronically exposed to HDM allergen. These findings were consistent with other in vivo studies that have reported that CTGF mRNA and protein are up-regulated in animal models of allergic airways disease. CTGF was also enhanced in lung tissue from severe asthmatic patients, compared to non-asthmatic controls. The ASM cells, as the primary source of CTGF in lung tissue, are uniquely positioned to drive remodelling (new blood vessel formation and BM thickening) as they lie immediately below the lamina propria, a major location of vascular expansion and ECM deposition in remodelling airways.
To illuminate the cause of the difference in regulation of CTGF mRNA between A- and NA-ASM cells, we investigated transcriptional and post-transcriptional regulation of CTGF in primary ASM cells. The well-characterized TGF-β responsive elements in the CTGF promoter appeared to not be involved in the regulation of CTGF in ASM cells. However, the CTGF promoter constructs used in this study do not integrate into the chromatin. As such, the promoter constructs are not subject to the same epigenetic controls as the TGF-β responsive elements in the endogenous gene which may account for some of the discrepancy. Our discovery of a novel CTGF transcriptional regulatory region, upstream of what is considered to be the core promoter region, in lung fibroblasts opens new realms in the tissue specific regulation of CTGF expression. Given the similarities in gene expression, we speculate that this mechanism is likely to play a role in the unique regulation of CTGF in lung mesenchymal cells; however, the absence of ASM data precluded our validation in ASM directly and this is a limitation of our study. We have previously shown TGF-β induced CTGF through activation of the extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K) signalling pathways in ASM cells. ERK is known to be linked to SMAD2/3 activation and likely targets the traditional core promoter region (−1300 to −200 bp) of CTGF which appears to be SMAD sensitive (Figure 4). However, PI3K has not been associated with SMAD 2/3 signalling to date and therefore may target the alternative promoter regulatory region we have identified in this study. Moreover, how these distant genomic elements are recruited to the core promoter to modulate CTGF expression is unknown and may be influenced by epigenetic modification of histones (particularly K27 acetylation) which is readily acknowledged to be different in asthmatic and healthy airways. Further research is necessary to identify the transcriptional regulatory elements, potentially within the −4200- to −2400-bp region, activated by these alternative signalling pathways for driving CTGF expression.

The similarities in basal promoter activity in A- and NA-ASM were just as surprising as the lack of TGF-β responsiveness in the CTGF promoter. We identified that the basal promoter in ASM is located between −100 and −400 bp. This region contains predicted binding sites for SMAD, AP1, TGF-β element, Ets1, NF-1-like sequence, TIE-like site amongst others. Some of these factors have previously been implicated in TGF-β signalling whilst others have not. The similarity of basal CTGF promoter activity in A- and NA-ASM underscores the importance of the inflammatory milieu in the asthmatic airway in directing the phenotype of ASM during disease.

We also showed that CTGF mRNA stability was enhanced in A-ASM cells. Chowdhury and colleagues previously showed this to be mediated by p38 in bladder smooth muscle cells. However, our previous data conclusively showed this pathway is not involved with CTGF regulation by TGF-β in A-ASM. The mechanism underlying this enhanced CTGF mRNA stability is currently unknown.

The dysregulation of CTGF in asthmatic airways may have profound consequences for disease progression, as suggested by the association of CTGF gene expression levels with BM thickening in our patient cohort. One limitation in our study is that the biopsies from which we obtained the gene signal were of a mixed cell population and we have no information about the ASM content in each biopsy. This may have altered the CTGF gene signal as CTGF is also expressed by airway epithelial cells and fibroblasts and it is not known if these levels are also altered in asthma. If the epithelial gene expression of CTGF is not increased in asthma, this may have reduced the strength of the association we observed with BM thickness. The BM is 2- to 3-fold thicker in asthmatic compared to healthy airways and is associated with increased airway resistance, limitations to airflow and decreased lung function. Association of BM thickening with poor clinical outcome is somewhat controversial with adults but shows better correlation in children. The thicker BM of asthmatic airways also has an altered elastic modulus compared to healthy airways. The increased ECM stiffness that accompanies such a change is likely to contribute to the pro-remodelling environment found in asthmatic airways as stiffer matrices promote angiogenesis and ASM cell proliferation. Indeed, stiffer matrices may also enhance CTGF expression through Taz activation completing a positive feedback loop in the asthmatic airway that would co-ordinate all aspects of airway remodelling (ASM bulk, neovascularization and BM thickening).

In conclusion, our data strongly suggest that the unique regulatory mechanisms that underpin the enhanced CTGF expression in A-ASM are pivotal for the development of airway remodelling. Thus, CTGF represents an underappreciated target for future therapeutic intervention addressing an aspect of disease pathogenesis currently not effectively treated by existing approaches.

ACKNOWLEDGEMENTS

This study was supported by National Health and Medical Research Council of the Australian Government (NHMRC grant #1061712 [JKB, AWA] #454437 [KS], Fellowship #1032695 [JKB]), a research grant from GlaxoSmithKline and the University of Groningen and European Union Rosalind Franklin Fellowship (JKB).

CONFLICTS OF INTERESTS

The authors confirm there are no conflict of interests in this study.

ORCID

Anthony W. Ashton http://orcid.org/0000-0001-6063-1566

REFERENCES

3. Burgess JK. The extracellular matrix: friend or foe in airway disease? 


45. Xu X, Wan X, Geng J, Li F, Yang T, Dai H. Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via...


SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.